Global Alzheimer's Disease Industry Forecast, 2032: Breakthrough Therapies and Market Trends
August 23, 2023 05:53 ET | Research and Markets
Dublin, Aug. 23, 2023 (GLOBE NEWSWIRE) -- The "Global Alzheimer's Disease Market 2023-2032" report has been added to ResearchAndMarkets.com's offering. Alzheimer's disease, a progressive...
Global Alzheimer’s Disease Diagnostics and Therapeutics Market
Alzheimer's Disease Diagnostics and Therapeutics Global Market Report 2023: Increasing Use of Biomarkers for Diagnosis Drives Growth
February 17, 2023 10:38 ET | Research and Markets
Dublin, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The "Alzheimer's disease diagnostics and therapeutics Market, by Product, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030"...
Alzheimer’s Disease Therapeutics (2022 Edition) – Market
World Alzheimer's Disease Therapeutics Analysis Report 2022: A $4.26 Billion Market by 2028 - Market Insights, Epidemiology and Pipeline Assessments
February 15, 2023 06:58 ET | Research and Markets
Dublin, Feb. 15, 2023 (GLOBE NEWSWIRE) -- The "Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration,...
Alzheimer Disease Therapeutics Market
Global Alzheimer's Disease Therapeutics Market Research Report 2023: Forecasts, Epidemiology & Pipeline Analysis 2022-2028
February 08, 2023 10:23 ET | Research and Markets
Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "Alzheimer's Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis 2023-2028" report has been added to ResearchAndMarkets.com's...
Global Alzheimer Therapeutics Market
Global Alzheimer's Therapeutics Market Analysis Report 2022: A Potential $15.6 Billion Market by 2030
August 30, 2022 06:08 ET | Research and Markets
Dublin, Aug. 30, 2022 (GLOBE NEWSWIRE) -- The "Global Alzheimer's Therapeutics Market Size, Share & Trends Analysis Report by Product (Cholinesterase Inhibitors, Pipeline Drugs), by End Use, by...
Global Alzheimer Drugs Market Report 2022: A Market Valued at $6,537.0 Million in 2021 - Forecast to 2027
February 15, 2022 07:08 ET | Research and Markets
Dublin, Feb. 15, 2022 (GLOBE NEWSWIRE) -- The "Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By...
National Down Syndro
National Down Syndrome Organizations Launch Joint Effort To Change CMS Proposal Concerning Coverage For New Class Of Alzheimer’s Treatments
February 04, 2022 10:47 ET | National Down Syndrome Society
Atlanta, GA., Bismarck, ND., Burlington, MA., Denver, CO., Hoffman Estates, IL, NY, NY, Rockport, ME, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Down Syndrome Affiliates in Action (DSAIA), GiGi’s Playhouse...
Global Alzheimer's Disease Market Report 2021-2030: Current Landscape of the Marketed, Clinical and Preclinical Molecules Available/Being Developed for Treatment
November 24, 2021 02:48 ET | Research and Markets
Dublin, Nov. 24, 2021 (GLOBE NEWSWIRE) -- The "Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and...
Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer’s Disease
June 16, 2021 09:00 ET | Headlands Research
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- Headlands Research (www.headlandsresearch.com), a global next-generation clinical research site organization, is pleased to have supported Biogen...
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
October 22, 2019 06:30 ET | Biogen Inc.
New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints Based on...